SURYA-1: First in Human, Dose Escalation, Dose Expansion Study of AUR105 (clinicaltrials.gov) - Apr 17, 2026 - P1 | N=17 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=40 ➔ 17 | Recruiting ➔ Terminated; Patient recruitment problems.
Enrollment change • First-in-human • Trial termination • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Solid Tumor
|